Key result
The highest incidence of myocarditis or pericarditis after BNT162b2 vaccination was among male adolescents aged 16 to 17 years after dose 2 (15.7 per 100,000 doses; 95% CI, 9.7-23.9).
Why the study?
The risk of myocarditis or pericarditis after COVID-19 mRNA vaccines varies by age and sex, with emerging evidence suggesting higher risk with shorter interdose intervals, requiring evaluation in adolescents.
Population
Adolescents aged 12 to 17 years receiving approximately 1.65 million BNT162b2 doses in Ontario, Canada
Comparison
Age group, sex, dose number, and interdose interval
Design
Population-based cohort study using surveillance data linked to a vaccine registry
Authors
Loading...
Incidence varies by age, sex, and interdose interval in adolescents; leaves open optimal dosing intervals pending prospective trials.
Cohort (n=77)
Myocarditis or pericarditis after BNT162b2 vaccination in adolescents is a rare event, with the highest risk observed in males aged 16 to 17 years after the second dose, especially with a short interdose interval.
Buchan et al. (2023) conducted a cohort in Myocarditis or pericarditis (n=77). BNT162b2 vaccine was evaluated on Reported incidence of myocarditis or pericarditis meeting level 1 to 3 of the Brighton Collaboration case definition per 100 000 doses of BNT162b2 administered. The highest incidence of myocarditis or pericarditis after BNT162b2 vaccination was among male adolescents aged 16 to 17 years after dose 2 (15.7 per 100,000 doses; 95% CI, 9.7-23.9).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: